ISRCTN73941125已完成不适用
A randomised trial comparing epirubicin, cisplatin and protracted venous infusion (PVI) 5-Fluorouracil (5FU) (ECF) to 5FU, Etoposide Leucovorin (FELU) in patients with inoperable or metastatic biliary cancer
The Royal Marsden NHS Foundation Trust (UK)0 个研究点目标入组 0 人开始时间: 2002年8月19日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Histological locally advanced or metastatic adenocarcinoma, squamous carcinoma or undifferentiated carcinoma of the gallbladder, intra/extra-hepatic bile ducts or Ampulla of Vater
- •2. Measurable disease on Computed Tomography (CT), Magnetic Resonance Imaging (MRI) or radiograph
排除标准
- •Not provided at time of registration
研究者
相似试验
已完成
不适用
A randomized phase II trial comparing epirubicin, cisplatin, and capecitabine versus the combination of epirubicin, cisplatin, and capecitabine with pravastatin in patients with irresectable or metastatic gastric carcinomaCancerISRCTN23062732Erasmus Medical Center, Department of Medical Oncology (Netherlands)43
已完成
不适用
A randomised trial of epirubicin and cyclophosphamide versus epirubicin and paclitaxel in the treatment of women with metastatic breast cancerCancerBreast cancerISRCTN75147488Medical Research Council (MRC) (UK)700
进行中（未招募）
1 期
Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine and Herceptin in Early Breast Cancerearly HER-2 breast cancerEUCTR2004-002030-19-ATAUSTRIAN BREAST CANCER STUDY GROUP536
进行中（未招募）
不适用
?Fase II study with epirubicin, cisplatin and infusional fluorouracil (ECF) followed by weekly paclitaxel plus metronomic cyclophosphamide ? trastuzumab as preoperative treatment of locally advanced ER and PgR negative breast cancer?. - NDocally advanced breast cancerMedDRA version: 12.0Level: LLTClassification code 10057654Term: Breast cancer femaleEUCTR2009-012048-18-ITISTITUTO EUROPEO DI ONCOLOGIA
已完成
不适用
A randomised trial of epirubicin versus mitomycin C at the time of first recurrence in superficial bladder cancerBladder cancerCancerISRCTN77353795Medical Research Council (MRC) (UK)800